Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$13.67Cboe Real-Time Last Sale as of 10:42AM ET 8/07/20
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.11(0.80%)
Bid (Size)$13.65 (300)
Ask (Size)$13.70 (5)
Day Low / High$13.57 - 13.86
Volume81.1 K
 

View Biotechnology IndustryPeer Comparison as of 08/07/2020

 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $13.67
Change: -0.11 (0.80%)
Volume: 81.1 K
10:42AM ET 8/07/2020
 
 

Dynavax Technologies Corp ( NASDAQ )

Price: $7.86
Change: -0.96 (10.88%)
Volume: 4.5 M
10:42AM ET 8/07/2020
 
 

Myriad Genetics Inc ( NASDAQ )

Price: $12.49
Change: +0.10 (0.81%)
Volume: 55.8 K
10:35AM ET 8/07/2020
 
 

Enanta Pharmaceuticals Inc ( NASDAQ )

Price: $46.82
Change: +0.51 (1.10%)
Volume: 6.4 K
10:35AM ET 8/07/2020
 
 

Stoke Therapeutics Inc ( NASDAQ )

Price: $27.01
Change: +0.51 (1.92%)
Volume: 3.2 K
10:36AM ET 8/07/2020
 

Read more news Recent News

Analyst Actions: RBC Capital Cuts Aimmune Therapeutics's Price Target to $40 From $52, Maintains Outperform-Speculative Risk Rating
7:26AM ET 7/31/2020 MT Newswires

Aimmune Therapeutics' (AIMT) average rating among analysts is a buy, with an average price target of $39. (MT Newswires covers equity, commodity and...

-- Earnings Flash (AIMT) AIMMUNE THERAPEUTICS INC. Reports Q2 EPS $-0.81
4:14PM ET 7/30/2020 MT Newswires

...

--Analyst Actions: Credit Suisse Cuts Price Target on Aimmune Therapeutics to $15 From $19, Maintains Neutral Rating
9:36AM ET 7/29/2020 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Analyst Actions: Cowen Starts Aimmune Therapeutics at Outperform With $35 Price Target
9:23AM ET 7/13/2020 MT Newswires

Aimmune Therapeutics (AIMT) has an average buy rating among analysts, with an average price target of $40. (MT Newswires covers equity, commodity and...

Company Profile

Business DescriptionAimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. View company web site for more details
Address8000 Marina Boulevard
Brisbane, California 94005-1884
Phone+1.650.614.5220
Number of Employees215
Recent SEC Filing07/31/202010-Q
President, Chief Executive Officer & DirectorJayson Donald Alexander Dallas
Chief Financial OfficerEric Hands Claude Bjerkholt
Chief Medical OfficerDaniel C. Adelman
Executive Vice President-Technical OperationsNarinder Singh

Company Highlights

Price Open$13.78
Previous Close$13.78
52 Week Range$10.09 - 37.00
Market Capitalization$894.7 M
Shares Outstanding65.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/04/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.44
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-48,810.96%
Return on Equity-161.13%

Analyst Ratings as of 07/10/2020

Buy
6
Overweight
1
Hold
5
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset